Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study

Keunchil Park,Eric B. Haura,Natasha B. Leighl,Paul Mitchell,Catherine A. Shu,Nicolas Girard,Santiago Viteri,Ji Youn Han,Sang-We Kim,Chee Khoon Lee,Joshua K. Sabari,Alexander I. Spira,Tsung-Ying Yang,Dong-Wan Kim,Ki Hyeong Lee,Rachel E. Sanborn,José Manuel Trigo,Koichi Goto,Jong Seok Lee,James Chih-Hsin Yang,Ramaswamy Govindan,Joshua Bauml,Pilar Garrido,Matthew G Krebs,Karen L. Reckamp,John Xie,J.C. Curtin,Nahor Haddish-Berhane,A. Roshak,Dawn Millington,Patricia Lorenzini,Meena Thayu,Roland Elmar Knoblauch,Byoung Chul Cho

Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study

2021

PURPOSENon–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. A...

Keywords:

Tyrosine kinase
Exon
Epidermal growth factor receptor
Cancer research
non small cell
Medicine
phase i study
Lung cancer
platinum chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations